GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline PLC ( GSK , Financial) is ready for a “landmark year,” CEO Emma Walmsley said at Tuesday's session of the 40th Annual JP Morgan Health Care Conference.

Glaxo CEO: 2022 Will be 'Landmark' Year for Company

Vir Biotechnology

The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy for an undisclosed sum. The companies would supply the additional doses of sotrovimab to the U.S. in Q1 of 2022, taking the tally of doses secured by nations worldwide to roughly 1.7 million.

US To Purchase 600K Additional Doses of GSK-Vir's COVID-19 Antibody Therapy

GlaxoSmithKline GSK, -0.60% GSK, +0.83% and partner Vir Biotechnology VIR, +1.96% said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for early COVID-19 treatment. The extra doses will be delivered in the first quarter of 2022 to the U.S., which has an option to purchase more in the second quarter.

GlaxoSmithKline, Vir shares up as U.S. orders more doses of COVID treatment sotrovimab

The new deal brings to 1 million the total number of doses of the therapy that the U.S. government has purchased, according to GlaxoSmithKline.

Glaxo and Vir Sell 600,000 Covid Antibody Doses to U.S.

GlaxoSmithKline GSK, +2.26% GSK, +1.24% and partner Vir Biotechnology VIR, -0.62% said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for early COVID-19 treatment. The extra doses will be delivered in the first quarter of 2022 to the U.S., which has an option to purchase more in the second quarter.

GlaxoSmithKline to ship 600,000 more doses of COVID treatment sotrovimab to U.S.

908 Devices

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional REBEL™ cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams. “We are pleased that GSK has once again chosen our REBEL desktop device as part of its process development efforts to br

908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer

GlaxoSmithKline PLC GSK, -0.18% announced Thursday an agreement to supply the Government of Canada with 20,000 doses of Sotrovimab, the COVID-19 monoclonal antibody therapy the company developed with Vir Biotechnology Inc. VIR, +0.20% . The agreement follows Canada's initial order of 10,000 doses of Sotrovimab announced in October, which included options for additional purchases.

GlaxoSmithKline, Vir increases supply of COVID-19 antibody therapy to Canada to 20,000 doses

BiondVax Pharmaceuticals

JERUSALEM, Dec. 27, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that all proposed resolutions were approved at today's Annual General Meeting of Shareholders, including the election of Mr.

Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors

Glaxo's (GSK) Apretude is the first and only long-acting injectable therapy approved for HIV prevention or PrEP.

Glaxo (GSK) Gets FDA Nod for HIV Preventive Injectable Drug

Micron Technology

NIKE

Pfizer

Stock futures steady as investors consider the Omicron variant among other factors weighing on markets.

Stock Market Today: Stock Futures Rise After Omicron-Led Sell-Off; Nike and Micron Soar On Strong Earnings; Pfizer and GSK Make FDA Breakthrough With HIV Drug

The FDA has approved ViiV Healthcare's Apretude, the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option, to reduce the risk of sexually acquired HIV-1.  The long-acting injectable was approved for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV and have a negative HIV-1 test before initiation.

Long-Acting HIV Treatment Backed By GSK, Pfizer Scores FDA Approval As Preventative Option

GSK vs. NVO: Which Stock Is the Better Value Option?

Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission's nod for Xevudy for the early treatment of COVID-19.

Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19

Cardinal Health

Costco

Smith & Wesson Brands

Watching the developments of the Covid-19 crisis, it could become endemic. Here's what that means for certain stocks to buy.

7 Stocks to Buy if Covid-19 Becomes Endemic

AstraZeneca

Regeneron Pharmaceuticals

We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.

Omicron Variant Puts COVID-19 Antibody Treatments in Focus

GlaxoSmithKline PLC (LSE:GSK) said it appointed Sir Dave Lewis, the former boss of Tesco PLC (LSE:TSCO), as chair of its new consumer healthcare arm, which is due to be spun off next year. Lewis left Tesco in September this year after six years as chief executive of the supermarket giant.

GlaxoSmithKline names ex-Tesco chief Sir Dave Lewis to chair consumer healthcare spin-off

LONDON (Reuters) -GlaxoSmithKline on Monday named former Tesco CEO Dave Lewis as non-executive chair designate of a new Consumer Healthcare company to be created from a proposed demerger from GSK in 2022.

Former Tesco boss Lewis to chair GSK health spin-off

GlaxoSmithKline Plc has picked former Chief Executive Officer of Tesco Plc Dave Lewis to head GSK's consumer healthcare unit, which is being spun off into a standalone business, Sky News reported on Sunday.

GSK picks ex-Tesco chief Lewis to head spun-off consumer healthcare arm - Sky News

The European Commission (EC) has granted marketing authorization to GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) Xevudy (sotrovimab) for the early treatment of COVID-19.  Sotrovimab is now approved in the European Union (EU) for adults and adolescents (aged 12 years & above and weighing at least 40kg) with COVID-19 who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19.

Glaxo-Vir Biotech's Antibody Approved In Europe For Early Treatment Of COVID-19

As of October, GlaxoSmithKline had 4 drugs in registration and 24 drugs in phase 3 trials.

GlaxoSmithKline: Healthcare GARP Following Separation

23andMe

These two companies have massive growth opportunities and have declined sharply in recent months.

2 Cheap Stocks With 10X Potential to Buy in 2022

GlaxoSmithKline (GSK) closed at $43.66 in the latest trading session, marking a +1.77% move from the prior day.

GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know

Sanofi

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year. The news came as the companies shared preliminary data from trials that showed the single-dose booster provided strong immune responses.

Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back

The vaccine's release will be pushed back to 2022 following delays to main clinical trials, the companies said.

Sanofi, GSK Say Covid Vaccine Works As Booster Shot

GlaxoSmithKline PLC (LSE:GSK) said the Covid-19 vaccine it is developing with French group Sanofi proved effective as a booster shot in a major independent trial. The vaccine boosted Covid-neutralising antibodies by a factor of 9 to 43 whatever primary vaccines ((AstraZeneca, Johnson & Johnson (NYSE:JNJ), Moderna, Pfizer/BioNTech) had been received and for all age groups with good safety and tolerability.

News for GlaxoSmithKline Stock (GSK)